SHENZHEN, CHINA and ROCKVILLE, MD, October 10, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that multiple abstracts for HTD1801...

HighTide Therapeutics (“HighTide”) and Silexon Tech (“Silexon”) jointly announced a long-term strategic collaboration agreement in new drug research and development.

Based on Safety Data Review, DMC Recommends Continuing Trial